Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 111109 | Other Identifier | PaNaMa |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this prospective intervention study is to investigate the effectiveness of redispensing unused oral anticancer drugs.
The main questions it aims to answer are:
Researchers will compare redispensing unused oral anticancer drugs to the standard practice of disposal.
Participants will receive their oral anticancer drugs in a sealed bag with a temperature indicator if needed. They will be asked to return any unused oral anticancer drugs to the pharmacy during their next visit to the hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| redispensing oral anticancer drugs | Other | Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them. Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:
Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy. |
| Measure | Description | Time Frame |
|---|---|---|
| The environmental impact of redispensing unused oral anticancer drugs of verified quality compared to standard practice of disposal. | Environmental impact will be measured in CO2-eq | From date of first dispensing unit the date of last unused medication package returning to the pharmacy, assessed up to 16 months |
| Cost-savings obtained by redispensing unused oral anticancer drugs of verified quality compared to standard practice of disposal. | Cost savings will be measured in euros | From date of first dispensing unit the date of last unused medication package returning to the pharmacy, assessed up to 16 months. |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of usability of returned medication for redispensing and the reasons for quality disapproval. | From date of first dispensing unit the date of last unused medication package returning to the pharmacy, assessed up to 16 months | |
| The proportion of returned unused oral anticancer drugs and reasons thereof. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shirley Xie | Contact | 0611469114 | Shirley.Xie@radboudumc.nl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboudumc | Recruiting | Nijmegen | Gelderland | 6525 GA | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From date of first dispensing unit the date of last unused medication package returning to the pharmacy, assessed up to 16 months |
| Patients' reasons for not wanting to participate in a redispensing program for oral anticancer drugs. | From date of first invitation to participate in the study until the end of the recruitment period, up to 8 months. |